New vitamin D analogs

被引:36
作者
Slatopolsky, E [1 ]
Finch, J [1 ]
Brown, A [1 ]
机构
[1] Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA
关键词
uremia; hyperparathyroidism; calcium; phosphorus; cacitriol;
D O I
10.1046/j.1523-1755.63.s85.20.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. 1,25-(OH)(2)D-3 (calcitriol) controls parathyroid gland growth and suppresses the synthesis and secretion of parathyroid hormone. Because of this, 1,25-(OH)(2)D-3 has been used successfully for the treatment of secondary hyperparathyroidism, which almost always accompanies renal failure. However, the potent effect of 1,25-(OH)(2)D-3 on intestinal calcium and phosphorus absorption and bone mineral mobilization often leads to the development of hypercalcemia and hyperphosphatemia precluding 1,25-(OH)(2)D-3 therapy. Methods. This has led to the development of vitamin D analogs that retain the suppressive action on PTH and parathyroid gland growth, but that have less calcemic and phosphatemic activity. Currently, two analogs, 19-nor-1,25-(OH)(2)D-2 and 1,alpha(OH)D-2, are being used for the treatment of secondary hyperparathyroidism in the United States, and two are being used in Japan, 22-oxa-calcitriol and 1,25-(OH)(2)-26,27F6 D-3. Results. All four analogs suppressed PTH, but had less calcemic and phosphatemic activity than 1,25-(OH)(2)D-3. In rats, 19-nor-1,25-(OH)(2)D-2 has been shown to be less calcemic and phosphatemic compared to 1,alpha(OH)D-2. Conclusion. Therapeutic doses of 19-nor-1,25-(OH)(2)D-2 could produce a lower Ca x P product compared to 1,alpha(OH)D-2, which could be an important consideration in patient treatment. Further studies are necessary to define these differences and to understand the mechanisms behind the differential actions of vitamin D analogs.
引用
收藏
页码:S83 / S87
页数:5
相关论文
共 29 条
[1]   INTRAVENOUS CALCITRIOL IN THE TREATMENT OF REFRACTORY OSTEITIS FIBROSA OF CHRONIC RENAL-FAILURE [J].
ANDRESS, DL ;
NORRIS, KC ;
COBURN, JW ;
SLATOPOLSKY, EA ;
SHERRARD, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :274-279
[3]   STRUCTURE-FUNCTION-RELATIONSHIPS IN THE VITAMIN-D ENDOCRINE SYSTEM [J].
BOUILLON, R ;
OKAMURA, WH ;
NORMAN, AW .
ENDOCRINE REVIEWS, 1995, 16 (02) :200-257
[4]  
BROWN AJ, 1994, SEMIN NEPHROL, V14, P156
[5]   THE NONCALCEMIC ANALOG OF VITAMIN-D, 22-OXACALCITRIOL, SUPPRESSES PARATHYROID-HORMONE SYNTHESIS AND SECRETION [J].
BROWN, AJ ;
RITTER, CR ;
FINCH, JL ;
MORRISSEY, J ;
MARTIN, KJ ;
MURAYAMA, E ;
NISHII, Y ;
SLATOPOLSKY, E .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) :728-732
[6]   1,25-DIHYDROXYVITAMIN-D3 SUPPRESSES PARATHYROID-HORMONE SECRETION FROM BOVINE PARATHYROID CELLS IN TISSUE-CULTURE [J].
CANTLEY, LK ;
RUSSELL, J ;
LETTIERI, D ;
SHERWOOD, LM .
ENDOCRINOLOGY, 1985, 117 (05) :2114-2119
[7]   THE EFFECT OF 1,25 DIHYDROXYCHOLECALCIFEROL ON PARATHYROID-HORMONE SECRETION BY MONOLAYER-CULTURES OF BOVINE PARATHYROID CELLS [J].
CHAN, YL ;
MCKAY, C ;
DYE, E ;
SLATOPOLSKY, E .
CALCIFIED TISSUE INTERNATIONAL, 1986, 38 (01) :27-32
[8]   HYPERPHOSPHATEMIA - ITS CONSEQUENCES AND TREATMENT IN PATIENTS WITH CHRONIC RENAL-DISEASE [J].
DELMEZ, JA ;
SLATOPOLSKY, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (04) :303-317
[9]   PARATHYROID-HORMONE SUPPRESSION BY INTRAVENOUS 1,25-DIHYDROXYVITAMIN-D - A ROLE FOR INCREASED SENSITIVITY TO CALCIUM [J].
DELMEZ, JA ;
TINDIRA, C ;
GROOMS, P ;
DUSSO, A ;
WINDUS, DW ;
SLATOPOLSKY, E .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1349-1355
[10]   BIOLOGICAL-ACTIVITY OF 1,25-DIHYDROXYVITAMIN D2 AND 24-EPI-1,25-DIHYDROXYVITAMIN D2 [J].
DELUCA, HF ;
SICINSKI, RR ;
TANAKA, Y ;
STERN, PH ;
SMITH, CM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 254 (04) :E402-E406